TYRA
Tyra Biosciences Inc
NASDAQ · Biotechnology
$31.00
+1.54 (+5.23%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 572.13M | 572.72M | 559.98M |
| Net Income | -99,921,707 | -80,567,499 | -92,627,690 |
| EPS | — | — | — |
| Profit Margin | -17.5% | -14.1% | -16.5% |
| Rev Growth | +16.0% | -4.7% | +5.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 492.39M | 558.04M | 500.43M |
| Total Equity | 999.86M | 1.02B | 990.43M |
| D/E Ratio | 0.49 | 0.55 | 0.51 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -119,066,634 | -104,548,216 | -110,415,827 |
| Free Cash Flow | -98,412,160 | -88,741,836 | -111,480,768 |